Brokaw, Crystal to be guests at NACDS annual meeting
ALEXANDRIA, Va. The National Association of Chain Drug Stores announced it will have two guests for its 2008 Annual Meeting.
NACDS said journalist/author Tom Brokaw and actor-comedian Billy Crystal will be in attendance at the annual meeting, which will take place April 26-30, 2008 at The Breakers Hotel in Palm Beach, Fla.
Chief executive officer and president of NACDS, Steve Anderson, said the two celebrities will “enhance the experiences of meeting attendees.”
“NACDS is honored to be able to host Billy Crystal and Tom Brokaw, such incredibly talented and distinguishable guests,” Anderson said. “The NACDS Annual Meeting offers opportunities for attendees to strengthen relationships, discuss strategic issues and identify enhanced business prospects with retailers in the pharmacy industry.”
Sandoz completes $10 million expansion of N.C. facility
WILSON, N.C. Sandoz recently completed the major phase of its Wilson, North Carolina expansion when over 50 employees moved into a new 30,000 square foot building.
Over 65 new jobs are expected to be created in Wilson as a result of the $10 million expansion. The positions will be filled by pharmaceutical scientists and analytical chemists and will bring the total of employees at the site to almost 480.
“The new laboratories present an excellent workplace and opportunity for top scientists to help us continue to growth in the U.S.,” said Bernhard Hampl, president and chief executive officer of Sandoz. “The new products developed at the site will be the basis for the future growth of the Wilson site.”
Pfizer, Taisho sign letter of intent over schizophrenia drug candidate
TOKYO and NEW YORK Taisho Pharmaceuticals and Pfizer have concluded on a letter of intent with regard to Taisho’s new drug candidate for schizophrenia, TS-032.
The drug is currently in the pre-clinical stage and the letter of intent relates to a proposed license agreement regarding rights for development and commercialization.
Through the agreement, Taisho will grant exclusive development and commercialization rights outside Japan for the drug to Pfizer. Once the agreement is signed, Taisho will receive an initial payment of $22 million as well as milestone and royalties linked to the development and sales of the drug.